Lead Product(s) : VLPM01
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Nobelpharma
Deal Size : $21.0 million
Deal Type : Series A Financing
Details : With this funding, VLPT aims to further accelerate the research and development of a cancer treatment vaccine as well as prophylactic vaccines including VLPM01, against malaria, dengue, etc. and move into clinical trials at the earliest date possible.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 27, 2021
Lead Product(s) : VLPM01
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Nobelpharma
Deal Size : $21.0 million
Deal Type : Series A Financing
Lead Product(s) : VLPM01
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 08, 2019
Lead Product(s) : VLPM01
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
